The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
05-Jul-21
Undisclosed
Target:
American Stock Transfer & Trust Company
Acquiror:
Siris Capital Group LLC
Advised Siris Capital, a private equity firm focused on the technology sector, on its acquisition of American Stock Transfer & Trust Company, a leading technology-enabled full service professional services firm
11-Jun-21
$248 million
Target:
My Alarm Center
Acquiror:
Ad Hoc Group of First Lien Lenders
Advised the Ad Hoc Group of First Lien Lenders on the pre-packaged Chapter 11 restructuring of My Alarm Center, a provider of security and smart home monitoring services
07-Jun-21
Undisclosed
Target:
Rights to General, Right Guard and Dry Idea brands
Acquiror:
N/A
Advised Henkel on its brand divestment program (including the sale of the General, Right Guard and Dry Idea brands)
01-Jun-21
Undisclosed
Target:
VEP Healthcare
Acquiror:
U.S. Acute Care Solutions
Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions
27-May-21
$1.4 billion
Target:
Equiniti Group PLC
Acquiror:
Siris Capital Group LLC
Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist
10-May-21
Pending
N/A
Target:
International Flavors & Fragrances, Inc.’s Fruit Preparations business
Acquiror:
Frulact Serviços Partilhados, SA
Advised International Flavors & Fragrances on the divestiture of its European-based Fruit Preparation business to Frulact Serviços Partilhados, SA
07-May-21
N/A
Target:
MindPath Care Centers
Acquiror:
Community Psychiatry
Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US
31-Mar-21
$801 million
Target:
Assets of NPC International, a former national Wendy’s and Pizza Hut franchisee
Acquiror:
Flynn Restaurant Group and a consortium of existing Wendy’s franchisees
Advised the Company on its chapter 11 proceedings and $801mm sale through a § 363 process
18-Mar-21
$750 million
Target:
Canopy Growth Corporation
Acquiror:
King Street Capital Management, L.P.
Advised Canopy Growth, a leading diversified cannabis company, on its US$750 million term loan financing with King Street Capital Management, L.P.
26-Feb-21
$2.0 billion
Target:
MDLIVE
Acquiror:
Cigna
Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio
25-Feb-21
$1.5 billion
Target:
Ascena Retail Group, Inc.
Acquiror:
Sycamore Partners
Advised the Ad Hoc Group of First-Lien Term Loan lenders of Ascena Retail Group, Inc. with respect to (i) negotiation of a restructuring support agreement, including a fully backstopped DIP and exit financing and (ii) a sale of Ann Taylor, LOFT and Lane Bryant as well as the intellectual property assets of the Justice and Catherine’s brands.
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
13-Nov-20
$495 million
Target:
Libbey, Inc.
Acquiror:
N/A
Advised the Committee of Unsecured Creditors on the in-court restructuring of Libbey, Inc., a leading tableware manufacturer
13-Nov-20
$343 million
Target:
Revlon Consumer Products Corporation
Acquiror:
N/A
Advised Ad Hoc Group of Note Holders with respect to Revlon’s Exchange Offer
16-Oct-20
$430 million
Target:
Alert 360 (Central Security Group, Inc.)
Acquiror:
N/A
Advised the Ad Hoc Group of First Lien Lenders on the out-of-court restructuring of Alert 360 (Central Security Group, Inc.), a leading home-security provider
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
30-Sep-20
$236 million
Target:
J. Jill, Inc.
Acquiror:
TowerBrook Capital Partners L.P.
Advised TowerBrook Capital Partners L.P., a leading investment management company and majority shareholder of J. Jill, on the comprehensive out-of-court recapitalization of J. Jill
15-Sep-20
$NA
Target:
Surgery Partners’ Anesthesia Services
Acquiror:
NorthStar Anesthesia
Advised Surgery Partners, a leading owner and operator of surgical facilities, on the divestiture of its anesthesia services business to NorthStar Anesthesia
12-Aug-20
$225 million
Target:
340B Link
Acquiror:
Omnicell
Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)
01-Jul-20
$225 million
Target:
Cello Health plc
Acquiror:
Arsenal Capital Partners
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
11-Jun-20
$760 million
Target:
CSM Bakery Solutions
Acquiror:
Rhône Group
Advised the Ad-Hoc Group of First Lien and Second Lien Lenders on consensual out-of-court amend & extend
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
03-Jun-20
$NA
Target:
Cerner RevWorks
Acquiror:
R1 RCM
Advised Cerner Corporation, a leader in healthcare information technology, on its sale of its RevWorks revenue cycle management services business to R1 RCM, a leading provider of technology-enabled RCM services